MRPMedical Research and Practice2993-96902993-9704Art and Design10.61369/MRP.2025040023Article低剂量 PEG-rhG-CSF 预防乳腺癌AT方案新辅助化疗粒细胞缺乏的临床研究https://artdesignp.com/journal/MRP/3/4/10.61369/MRP.2025040023张素玲,潘法雷,李熠,郭文静,位春红2025342025-04-20目的：AT方案作为乳腺癌新辅助化疗最常用治疗方案之一，不可避免的会出现粒细胞降低。本研究探讨了低剂量PEG-rhG-CSF（聚乙二醇化重组人粒细胞集落刺激因子）预防乳腺癌AT方案新辅助化疗粒细胞缺乏的疗效与安全性。方法：将60例乳腺癌患者随机（1∶1）纳入研究。30例随机分配到实验组的患者化疗后接受低剂量（3mg）PEG-rhG-CSF预防粒细胞缺乏，30例随机分配到对照组的患者不接受PEG-rhG-CSF预防粒细胞缺乏。主要终点是3-4级中性粒细胞减少(ANC<1.0x10    9/L)的发生率及恢复时间。次要研究终点包括发生发热性中性粒细胞减少（febrile    neutropenia，FN）患者的发生率(体温≥38.2  ℃，且ANC <  0.5  x  10 9 /L)及恢复时间。结果：与对照组患者相比，实验组患者3-4级中性粒细胞减少和FN发生率均明显降低（3-4级，P＜0.001；FN，P＜0.05），且中性粒细胞减少症恢复时间（平均±标准差）明显缩短（P＜0.05），且实验组患者3-4级中性粒细胞减少及FN恢复时间随化疗周期逐渐缩短。亚组分析实验组患者无论年龄是否≥60岁在3-4级中性粒细胞减少恢复时间上均较对照组明显缩短，且差异有统计学意义（P＜0.05）。两组患者分别：实验组：17例，56.7%，对照组：15例，50%，报告了任何级别的不良事件（AEs）。未见≥3级AEs的报告。结论：乳腺癌AT方案新辅助化疗后应用低剂量PEG-rhG-CSF，能够显著降低3-4级中性粒细胞减少和FN的发生率及恢复时间，应用更方便，且不增加患者不良反应，值得临床推广。乳腺癌,新辅助化疗,AT,中性粒细胞缺乏,FN,低剂量PEG-rhG-CSF

[1]Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2022;69(3):313- 317. doi:10.1007/s13304017-0424-1 . [2] Wei C, Wang Y, Li X. The role of Hippo signal pathway in breast cancer metastasis. Onco Targets Ther. 2018;11:2185-2193. doi:10. 2147/OTT.S157058 . [3] Li N, Deng Y, Zhou L, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017. J Hematol Oncol. 2019;12(1):140. doi:10.1186 /s13045-019- 0828-0. [4]黄香，殷永梅.2018年中国临床肿瘤学会乳腺癌治疗指南更新要点究[J].中华医学杂志，2022,98（16）：1213-1217.DOI：10.3760/cma.j.issn.0376-2491.2018.16.005. [5]Brown T, Sykes D, Allen AR. Implications of breast cancer chemotherapy-induced inflammation on the gut, liver, and central nervous system. Biomedicines. 2021;9(2):189. doi:10.3390/ biomedicines9020189. [6] Lally J, Malik S, Whiskey E, et al. Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating fa ctor /granulocyte-macrophage colony-stimulating factor: a systematic review. J Clin Psychopharmacol. 2017;37(4):441-446. doi:10. 1097/JCP.0000000000000715 [7]Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016;22(5):702-716. doi:10.1177/ 1078155215625459. [8]Gladkov O, Moiseyenko V, Bondarenko IN, et al. A phase III study of balugrastim versus pegfilgrastim in breast cancer patients receiving emotherapy with doxorubicin and docetaxel. Oncologist. 2022; 21(1):7-15. doi:10.1634/theoncologist. 2015-0152 [9]陈雨媛,郭瑢,黄胜,杨银菊,王常安,汤琦,王建逵,周绍强,陈德滇.聚乙二醇化重组人粒细胞刺激因子预防乳腺癌剂量密集化疗后的中性粒细胞减少[J].昆明医科大学学报 ,2020,41(09):26-31. [10]Dumbuya JS, Chen L, Shu SY, et al. G-CSF attenuates neuroinflammation and neuronal apoptosis via the mTOR/p70SK6 signaling pathway in neonatal hypoxia-ischemia rat model. Brain Res. 2020;1739:146817.doi:10.1016/j.brainres.2020.146817 [11]Qin Y, Han X, Wang L, et al. A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia. Chin J Cancer Res. 2019;29(5): 402-410. doi:10.21147/j.issn.1000-9604.2017.05.04 [12]Yoshida T, Nakamura S, Ohtake S, et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin’s lymphoma. Cancer. 2022;66(9):1904-1909. doi:10.1002/1097-0142(19901101) 66:9< 1904::AID-CNCR2820660908>3. 0.CO;2-V. [13]Ashrafi F, Salmasi M. Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients. J Res Med Sci. 2018;23 (1) :73. doi:10.4103/ jrms.JRMS_463_17 . [14]Wu FP, Wang J, Wang H, et al. Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colonystimulating factor in patients with concurrent chemoradiotherapyinduced grade IV neutropeni.  Exp Ther Med. 2017;9(3):761-765. doi: 10.3892/etm.2014.2160. [15]Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. PMID: 37061269. [16].Impact of dose intensity on pathologic complete response in neoadjuvant chemotherapy for breast cancer: a meta-analysis: Breast Cancer Research and Treatment DOI:[10.1007/s10549-020-05616-3] [17]Blackwell K, Donskih R, Jones CM, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT -2), a phase III, randomized, double-blind trial. Oncologist. 2016;21(7):789-794. doi:10.1634/ theoncologist.2016-0011. [18]Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapyinduced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2021;25 (11):3295-3304. doi:10.1007/s00520- 017-3842-1. [19]Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2022;50(5):295-306. doi:10.2165/ 11586040. [20]Baumann A, Tuerck D, Prabhu S, Dickmann L, Sims J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov Today. 2014;19(10):1623-1631. doi:10.1016/j. drudis.2022.06.002. [21]黄国兴，苏国森，李上芹等。３种新辅助化疗方案治疗乳腺癌的有效性和安全性比较［Ｊ］．中华实用诊断与治疗杂志，2023，34（2）：203-206．[22]尤赛男,丁磊,孟浩杰,杨宇欣,陈锐,查小明.聚乙二醇化人重组粒细胞刺激因子防治乳腺化疗后骨髓抑制的临床研究[J].南京医科大学学报(自然科学版),2020,40(05):693696. [23]Byun Jong Hyuk,Jung Il Hyo.Phase-specific cancer-immune model considering acqired resistance to therapeutic agents[J].Applied Mathematics and Computation,2022,(391):125 555. [24]Klastersky J, Awada A. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Crit Rev Oncol Hematol. 2021 Apr;78(1):17-23. [25]石远凯，许建萍，吴昌平，等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少症的多中心上市后临床研究［J］.中国肿瘤临床，2017，44（14）:679-684. [26]徐兵河，宋艳秋，王京芬，等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅱ期临床研究［J］.中国肿瘤临床与康复，2016，23（01）:3-7. [27]马军，朱军，徐兵河，等．聚乙二醇化重组人粒细胞刺激因子（PET－rhG－CSF）临床应用中国专家共识［Ｊ］．中 国肿瘤临床，2016，43（7）：271-274． [28]中国临床肿瘤学会指南工作委员会．肿瘤放化疗相关中性粒细胞减少症规范化管理指南［Ｊ］．中华肿瘤杂志，2018，39（11）：868-878．[29]Shi D, Beasock D, Fessler A, et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079. doi:10.1016 /j.addr.2022.114079. [30]Mey UJ, Maier A, Schmidt-Wolf IG, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer. 2022 ;15(7):877-884. doi:10.1007/ s00520-006-0201-z. [31]Xiaofeng Huang,Shuo Li,Wenjie Shi,et al.A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).Br J Clin Pharmacol.2023;89:372–379.DOI: 10.1111/bcp.15507. [32] KIRSHNER J J，MCDONALD M C，KRUTER F，et al. NOLAN：a randomized，phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with earlystage breast cancer receiving chemotherapy and pegfilgrastim［J］. Support Care Cancer，2018，26（4）：1323  1334.